Key result
Each 1-SD increase in admission ln(APAR) was associated with a higher risk of 90-day all-cause mortality (HR 1.375) in hospitalized patients with heart failure, though the association was modest and nonlinear.
Why the study?
The association between alkaline phosphatase-to-albumin ratio (APAR) at admission and early all-cause mortality within 90 days in hospitalized heart failure patients was unclear.
Does a higher admission alkaline phosphatase-to-albumin ratio (APAR) predict early all-cause mortality within 90 days in hospitalized patients with heart failure?
Cohort (n=1,906)
No
Does a higher admission alkaline phosphatase-to-albumin ratio (APAR) predict early all-cause mortality within 90 days in hospitalized patients with heart failure?
Hazard Ratio: 1.375 (95% CI 1.024–1.846)
p-value: p=0.034
Higher admission APAR is modestly associated with 90-day all-cause mortality in hospitalized heart failure patients, but its incremental value for clinical risk stratification appears limited.
Background APAR combines alkaline phosphatase and albumin, two routine laboratory measurements. We examined its association with recorded early all-cause mortality within 90 days of admission in hospitalized patients with heart failure (HF), prioritizing continuous APAR over a mortality-derived cutoff. Methods We analyzed version 1.3 of the Zigong Heart Failure Database. Among 2,008 patients, 1,906 had calculable APAR and a recorded vital-status outcome within 90 days; 37 deaths were recorded. Exact event times were available for 1,905 patients (36 deaths). The primary model assessed standardized ln(APAR), adjusting for the eight released age categories as a 1–8 ordinal score, sex, log(BNP), eGFR, sodium, and CCI, with NYHA class stratification. Mortality timing, post-discharge survival, hemoglobin adjustment, and E-values were examined in sensitivity analyses. Results Recorded all-cause mortality within 90 days of admission was 1.94%. In the complete-case model ( n = 1,824; 36 deaths), each 1-SD increase in ln(APAR) was associated with higher mortality (HR 1.375, 95% CI 1.024–1.846; P = 0.034), whereas raw APAR per 1 U/g was not (HR 1.146, 95% CI 0.988–1.330; P = 0.072). The spline showed an overall association ( P = 0.025) and nonlinearity ( P = 0.023). Nine of 37 deaths were confirmed in-hospital. Among 1,897 patients discharged without recorded in-hospital death, 28 died within 90 days: 15 on a later calendar date, 12 on the discharge date, and one with missing exact timing. In the strict post-discharge analysis, the adjusted HR was 1.460 (95% CI 0.931–2.289; P = 0.099; 15 events). APAR showed modest discrimination (AUC 0.698), while incremental value was limited: Δ C-index 0.018 ( P = 0.104), IDI 0.0019 (95% CI −0.0035 to 0.0252), small decision-curve gains, and continuous NRI 0.179 (95% CI −0.129 to 0.577). Conclusion Higher admission ln(APAR) was associated with recorded early all-cause mortality within 90 days of admission, but the association was modest, nonlinear, scale-dependent, and based on few events. Post-discharge estimates were directionally consistent but imprecise. External validation is required before APAR or any cutoff is used for clinical risk stratification.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) conducted a cohort in Heart failure (n=1,906). Alkaline phosphatase-to-albumin ratio (APAR) vs. Lower APAR was evaluated on All-cause mortality within 90 days of admission (HR 1.375, 95% CI 1.024-1.846, p=0.034). Each 1-SD increase in admission ln(APAR) was associated with a higher risk of 90-day all-cause mortality (HR 1.375) in hospitalized patients with heart failure, though the association was modest and nonlinear.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: